Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography

Phase 1

• Conditions: We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.

• Registration Number: EUCTR2005-005809-38-GB
• Lead Sponsor: Research & Development Department, Addenbrookes Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-01-10
• Study Completion: 2007-04-12
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Any patient undergoing peripheral angiography in Cambridge Vascular Unit,
Any patient that does not consent to participation in the study.
Any patient under the age of 18 years
Any patient with established renal failure on renal replacement therapy (dialysis).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified